Amanote Research
Register
Sign In
CD133, Selectively Targeting the Root of Cancer
Toxins
- Switzerland
doi 10.3390/toxins8060165
Full Text
Open PDF
Abstract
Available in
full text
Categories
Mutagenesis
Toxicology
Health
Date
May 28, 2016
Authors
Jörg Schmohl
Daniel Vallera
Publisher
MDPI AG
Related search
Selectively Targeting Estrogen Receptors for Cancer Treatment
Advanced Drug Delivery Reviews
Pharmaceutical Science
Characterization of Transgenic Mouse Lines for Selectively Targeting Glial Cells in Dorsal Root Ganglia
Selectively Targeting Prostate Cancer With Antiandrogen Equipped Histone Deacetylase Inhibitors
ACS Chemical Biology
Biochemistry
Medicine
Molecular Medicine
Characterization of the Conversion Between CD133+and CD133-cells in Colon Cancer SW620 Cell Line
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Delivery of Anti-miRNA for Triple Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting to Stem Cell Marker CD133
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Growth Kinetics of CD133-positive Prostate Cancer Cells
Prostate
Oncology
Urology
Prognostic Value of CD133 and SOX2 in Advanced Cancer
Journal of Oncology
Oncology
Targeting the Duality of Cancer
npj Precision Oncology
Evaluation of CD44 and CD133 as Cancer Stem Cell Markers for Colorectal Cancer
Oncology Reports
Medicine
Cancer Research
Oncology